Johnson & Johnson’s IMAAVY Delivers Breakthrough Results in wAIHA
STOCKHOLM, Sweden, June 11, 2026 Johnson & Johnson has reported positive pivotal Phase 2/3 results for IMAAVY® (nipocalimab-aahu) in...
anemia treatment
Advertisement
Agios Secures EU Approval for PYRUKYND in Thalassemia
Cambridge, Massachusetts, USA, May 22, 2026 Agios Pharmaceuticals has announced that the European Commission (EC) has granted marketing authorization...
High ESA Failure Rates Revealed in Lower-Risk MDS Real-World Study
September 22, 2025 — Florida, USA — A recent real-world retrospective study of 359 adult patients with lower-risk myelodysplastic...
Advertisement
